The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran
- PMID: 27522930
- PMCID: PMC5052375
- DOI: 10.1016/j.bjm.2016.07.016
The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran
Abstract
The aim of this study was to examine mutations in the quinolone-resistance-determining region (QRDR) of gyrA and parC genes in Pseudomonas aeruginosa isolates. A total of 100 clinical P. aeruginosa isolates were collected from different university-affiliated hospitals in Tabriz, Iran. Minimum inhibitory concentrations (MICs) of ciprofloxacin and levofloxacin were evaluated by agar dilution assay. DNA sequences of the QRDR of gyrA and parC were determined by the dideoxy chain termination method. Of the total 100 isolates, 64 were resistant to ciprofloxacin. No amino acid alterations were detected in gyrA or parC genes of the ciprofloxacin susceptible or ciprofloxacin intermediate isolates. Thr-83 → Ile substitution in gyrA was found in all 64 ciprofloxacin resistant isolates. Forty-four (68.75%) of them had additional substitution in parC. A correlation was found between the number of the amino acid alterations in the QRDR of gyrA and parC and the level of ciprofloxacin and levofloxacin resistance of the P. aeruginosa isolates. Ala-88 → Pro alteration in parC was generally found in high level ciprofloxacin resistant isolates, which were suggested to be responsible for fluoroquinolone resistance. These findings showed that in P. aeruginosa, gyrA was the primary target for fluoroquinolone and additional mutation in parC led to highly resistant isolates.
Keywords: Fluoroquinolone resistance; Pseudomonas aeruginosa; gyrA; parC.
Copyright © 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. All rights reserved.
Similar articles
-
gyrA and parC mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa from Nini Hospital in north Lebanon.J Infect Chemother. 2013 Feb;19(1):77-81. doi: 10.1007/s10156-012-0455-y. Epub 2012 Jul 21. J Infect Chemother. 2013. PMID: 22821356
-
Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.Int J Antimicrob Agents. 2005 Apr;25(4):290-5. doi: 10.1016/j.ijantimicag.2004.11.012. Int J Antimicrob Agents. 2005. PMID: 15784307
-
[Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].Zhonghua Yi Xue Za Zhi. 2003 Mar 10;83(5):403-7. Zhonghua Yi Xue Za Zhi. 2003. PMID: 12820918 Chinese.
-
Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem.J Med Microbiol. 2019 Jan;68(1):1-10. doi: 10.1099/jmm.0.000873. J Med Microbiol. 2019. PMID: 30605076 Review.
-
Mechanisms of fluoroquinolone resistance: an update 1994-1998.Drugs. 1999;58 Suppl 2:11-8. doi: 10.2165/00003495-199958002-00003. Drugs. 1999. PMID: 10553699 Review.
Cited by
-
Molecular Analysis of Pseudomonas aeruginosa Isolates with Mutant gyrA Gene and Development of a New Ciprofloxacin Derivative for Antimicrobial Therapy.Mol Biotechnol. 2024 Feb 1. doi: 10.1007/s12033-024-01076-y. Online ahead of print. Mol Biotechnol. 2024. PMID: 38302682
-
Molecular characterization and differential effects of levofloxacin and ciprofloxacin on the potential for developing quinolone resistance among clinical Pseudomonas aeruginosa isolates.Front Microbiol. 2023 Sep 8;14:1209224. doi: 10.3389/fmicb.2023.1209224. eCollection 2023. Front Microbiol. 2023. PMID: 37744929 Free PMC article.
-
Oxidative stress induced by Etoposide anti-cancer chemotherapy drives the emergence of tumor-associated bacteria resistance to fluoroquinolones.J Adv Res. 2024 Jan;55:33-44. doi: 10.1016/j.jare.2023.02.011. Epub 2023 Feb 21. J Adv Res. 2024. PMID: 36822389 Free PMC article.
-
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic.Front Public Health. 2022 Dec 21;10:1025633. doi: 10.3389/fpubh.2022.1025633. eCollection 2022. Front Public Health. 2022. PMID: 36620240 Free PMC article. Review.
-
Prevalence of Antimicrobial Resistance Genes in Salmonella Typhi: A Systematic Review and Meta-Analysis.Trop Med Infect Dis. 2022 Sep 27;7(10):271. doi: 10.3390/tropicalmed7100271. Trop Med Infect Dis. 2022. PMID: 36288012 Free PMC article. Review.
References
-
- Ahangarzadeh Rezaee M., Behzadiannezhad Q., Najjar-Pirayeh S., Oulia P. In vitro activity of imipenem and ceftazidime against mucoid and non-mucoid strains of Pseudomonas aeruginosa isolated from patients in Iran. Arch Iran Med. 2002;5:251–254.
-
- Lihua L., Jianhuit W., Jialini Y., Yayin L., Guanxin L. Effects of allicin on the formation of Pseudomonas aeruginosa biofinm and the production of quorum-sensing controlled virulence factors. Pol J Microbiol. 2013;62:243–251. - PubMed
-
- Wolska K., Szweda P. Genetic features of clinical Pseudomonas aeruginosa strains. Pol J Microbiol. 2009;58:255–260. - PubMed
-
- Ahangarzadeh Rezaee M., Behzadiannezhad Q., Najjar P.S., Oulia P. Higher aminoglycoside resistance in mucoid Pseudomonas aeruginosa than in non-mucoid strains. Arch Iranian Med. 2002;5:108–110.
-
- Oliveira ACd., Maluta R.P., Stella A.E., Rigobelo E.C., Marin J.M., Ávila FAd. Isolation of Pseudomonas aeruginosa strains from dental office environments and units in Barretos, state of São Paulo, Brazil, and analysis of their susceptibility to antimicrobial drugs. Braz J Microbiol. 2008;39:579–584. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical